The first subject has been dosed in the Phase III trial of the InnoCare Pharma’s novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332, for the treatment of atopic dermatitis (AD) in China.
ICP-332 is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders, including AD and vitiligo.
Currently, no TYK2 inhibitors have obtained marketing approval for the treatment of AD anywhere in the world.
ICP-332 achieved multiple efficacy endpoints in the China Phase II study for the treatment of patients with moderate-to-severe AD and demonstrated a good safety profile, the Company reported.
